Dietary n‑3 polyunsaturated fatty acids ameliorate Crohn's disease in rats by modulating the expression of PPAR‑γ/NFAT

Yao,Jiayin; Lu,Yi; Zhi,Min; Hu,Pinjin; Wu,Wei; Gao,Xiang

doi:10.3892/mmr.2017.7673

Dietary n‑3 polyunsaturated fatty acids ameliorate Crohn's disease in rats by modulating the expression of PPAR‑γ/NFAT

Authors:
- Jiayin Yao
- Yi Lu
- Min Zhi
- Pinjin Hu
- Wei Wu
- Xiang Gao
View Affiliations

Affiliations: Department of Gastroenterology, The Sixth Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510655, P.R. China, Department of Anesthesiology, Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong 510130, P.R. China, Department of Cardiology, Sun Yat‑Sen Memorial Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510235, P.R. China
Published online on: September 29, 2017 https://doi.org/10.3892/mmr.2017.7673
Pages: 8315-8322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dietary n‑3 polyunsaturated fatty acid (PUFA) exerts anti‑inflammatory and immunoregulatory effects via downregulation of the innate and adaptive immune responses. However, the effect of dietary n‑3 PUFA on experimental Crohn's Disease (CD) in rats and the underlying mechanisms are unclear. The present study aimed to investigate the effects of n‑3 PUFA on CD induced by 2,4,6‑trinitrobenzene sulfonic acid (TNBS) in rats, and to determine the underlying mechanisms, including the peroxisome proliferator‑activated receptor (PPAR)‑γ and nuclear factor of activated T‑cells (NFAT) pathway. Sprague‑Dawley rats (n=90) were randomly assigned to the following groups: Control (intragastric distilled water); PUFA control (intragastric n‑3 PUFA, 20 mg/kg/day); trans‑fatty acid (TFA) control (intragastric TFA, 13 mg/kg/day); model (intragastric distilled water + TNBS); PUFA model (intragastric n‑3 PUFA, 20 mg/kg/day + TNBS); and TFA model (intragastric TFA, 13 mg/kg/day + TNBS). The disease activity index (DAI), colon macroscopic damage index (CMDI) and tissue damage index (TDI) were evaluated. The expression of PPAR‑γ, NFAT, interleukin (IL)‑4 and IL‑2 mRNA in colonic tissues was determined by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), and the serum levels of IL‑6, IL‑12, tumor necrosis factor‑α and interferon‑γ were measured by ELISA. The results demonstrated that dietary n‑3 PUFA markedly attenuated colonic inflammation compared with the model group, as indicated by reduced DAI, CMDI and TDI scores, amelioration in pathological evaluation and improvements in localized mucosal inflammation, as indicated by the levels of cytokines associated with local mucosal immunity. Treatment with n‑3 PUFA increased the gene expression of PPAR‑γ in TNBS‑treated rats, and reduced the expression of NFAT, which ultimately reduced the release of IL‑4 and IL‑2 detected by RT‑qPCR. A TFA‑enriched diet was observed to increase DAI and TDI scores, aggravate pathological inflammation with epithelioid granulomas and enhance the release of proinflammatory cytokines, compared with the model group. In conclusion, the present study demonstrated that dietary n‑3 PUFA may attenuate experimental CD induced by TNBS in rats by regulating the expression and activity of the PPAR‑γ/NFAT signaling pathway. These results provide a promising potential therapeutic method for the treatment of CD.

View Figures

View References

1	Abraham C and Cho JH: Inflammatory bowel disease. N Engl J Med. 361:2066–2078. 2009. View Article : Google Scholar : PubMed/NCBI
2	Khor B, Gardet A and Xavier RJ: Genetics and pathogenesis of inflammatory bowel disease. Nature. 474:307–317. 2011. View Article : Google Scholar : PubMed/NCBI
3	Asakura H, Suzuki K, Kitahora T and Morizane T: Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? J Gastroenterol Hepatol. 23:1794–1801. 2008. View Article : Google Scholar : PubMed/NCBI
4	Thia KT, Loftus EV Jr, Sandborn WJ and Yang SK: An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 103:3167–3182. 2008. View Article : Google Scholar : PubMed/NCBI
5	Nakanishi S, Nagano C, Miyahara M and Sawano F: Sex differences in the association between the eicosapentaenoic acid/arachidonic acid ratio and the visceral fat area among patients with type 2 diabetes. Intern Med. 55:1269–1274. 2016. View Article : Google Scholar : PubMed/NCBI
6	Borgeraas H, Hertel JK, Seifert R, Berge RK, Bohov P, Ueland PM, Nygård O and Hjelmesæth J: Serum trans fatty acids, asymmetric dimethylarginine and risk of acute myocardial infarction and mortality in patients with suspected coronary heart disease: A prospective cohort study. Lipids Health Dis. 15:382016. View Article : Google Scholar : PubMed/NCBI
7	Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Fuchs CS, Willett WC, Richter JM and Chan AT: Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut. 63:776–784. 2014. View Article : Google Scholar : PubMed/NCBI
8	Marion-Letellier R, Savoye G, Beck PL, Panaccione R and Ghosh S: Polyunsaturated fatty acids in inflammatory bowel diseases: A reappraisal of effects and therapeutic approaches. Inflamm Bowel Dis. 19:650–661. 2013. View Article : Google Scholar : PubMed/NCBI
9	Yang Y, Lu N, Chen D, Meng L, Zheng Y and Hui R: Effects of n-3 PUFA supplementation on plasma soluble adhesion molecules: A meta-analysis of randomized controlled trials. Am J Clin Nutr. 95:972–980. 2012. View Article : Google Scholar : PubMed/NCBI
10	Calder PC: Mechanisms of action of (n-3) fatty acids. J Nutr. 142 Suppl:592S–599S. 2012. View Article : Google Scholar : PubMed/NCBI
11	Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, Gumucio DL, Marin HE, Peters JM, Young HA and Gonzalez FJ: Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut. 55:1104–1113. 2006. View Article : Google Scholar : PubMed/NCBI
12	Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA and Wu GD: A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest. 104:383–389. 1999. View Article : Google Scholar : PubMed/NCBI
13	Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C and Hontecillas R: Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria. PLoS One. 7:e346762012. View Article : Google Scholar : PubMed/NCBI
14	Zeng C, Xiao JH, Chang MJ and Wang JL: Beneficial effects of THSG on acetic acid-induced experimental colitis: Involvement of upregulation of PPAR-γ and inhibition of the Nf-Kb inflammatory pathway. Molecules. 16:8552–8568. 2011. View Article : Google Scholar : PubMed/NCBI
15	Hontecillas R, Horne WT, Climent M, Guri AJ, Evans C, Zhang Y, Sobral BW and Bassaganya-Riera J: Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. Mucosal Immunol. 4:304–313. 2011. View Article : Google Scholar : PubMed/NCBI
16	Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS, et al: Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology. 120:460–469. 2001. View Article : Google Scholar : PubMed/NCBI
17	Raman P, Kaplan BL, Thompson JT, Heuvel JP Vanden and Kaminski NE: 15-Deoxy-delta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl glycerol, activates peroxisome proliferator activated receptor gamma. Mol Pharmacol. 80:201–209. 2011. View Article : Google Scholar : PubMed/NCBI
18	Chung SW, Kang BY and Kim TS: Inhibition of interleukin-4 production in CD4⁺ T cells by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: Involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor. Mol Pharmacol. 64:1169–1179. 2003. View Article : Google Scholar : PubMed/NCBI
19	National Research Council, . Guide For The Care And Use Of Laboratory Animals. No. 85-23. National Academies Press; Washington, DC: 1996
20	Kilkenny C, Browne WJ, Cuthill IC, Emerson M and Altman DG: Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol. 8:e10004122010. View Article : Google Scholar : PubMed/NCBI
21	Mizoguchi A: Animal models of inflammatory bowel disease. Prog Mol Biol Transl Sci. 105:263–320. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wei W: Pharmacokinetics and bioavailability of drug metabolismExperimental Methodology of Pharmacology. 6th edition. People's Medical Publishing Company; Guangzhou: 2010, View Article : Google Scholar
23	Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, Imanishi J, Kita M, Ueda Y, Iwakura Y, et al: Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 146:330–338. 2006. View Article : Google Scholar : PubMed/NCBI
24	Yao JY, Lu Y, Zhi M, Li CJ, Hu PJ and Gao X: Inhibition of the interleukin-23/interleukin-17 pathway by anti-interleukin-23p19 monoclonal antibody attenuates 2,4,6-trinitrobenzene sulfonic acid-induced Crohn's disease in rats. Mol Med Rep. 10:2105–2110. 2014. View Article : Google Scholar : PubMed/NCBI
25	Ding H, Gan HZ, Fan WJ, Cao LY, Xu JM and Mei Q: Homocysteine promotes intestinal fibrosis in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci. 60:375–381. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zingarelli B, Hake PW, Burroughs TJ, Piraino G, O'Connor M and Denenberg A: Activator protein-1 signalling pathway and apoptosis are modulated by poly(ADP-ribose) polymerase-1 in experimental colitis. Immunology. 113:509–517. 2004. View Article : Google Scholar : PubMed/NCBI
27	Deepak P and Loftus EV Jr: Ustekinumab in treatment of Crohn's disease: Design, development, and potential place in therapy. Drug Des Devel Ther. 10:3685–3698. 2016. View Article : Google Scholar : PubMed/NCBI
28	Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, Gonzalez F, Rohrer J, Benninghoff AU and Hontecillas R: Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology. 127:777–791. 2004. View Article : Google Scholar : PubMed/NCBI
29	Viladomiu M, Hontecillas R, Yuan L, Lu P and Bassaganya-Riera J: Nutritional protective mechanisms against gut inflammation. J Nutr Biochem. 24:929–939. 2013. View Article : Google Scholar : PubMed/NCBI
30	Borniquel S, Jädert C and Lundberg JO: Dietary conjugated linoleic acid activates PPARγ and the intestinal trefoil factor in SW480 cells and mice with dextran sulfate sodium-induced colitis. J Nutr. 142:2135–2140. 2012. View Article : Google Scholar : PubMed/NCBI
31	Bassaganya-Riera J, DiGuardo M, Viladomiu M, de Horna A, Sanchez S, Einerhand AW, Sanders L and Hontecillas R: Soluble fibers and resistant starch ameliorate disease activity in interleukin-10-deficient mice with inflammatory bowel disease. J Nutr. 141:1318–1325. 2011. View Article : Google Scholar : PubMed/NCBI
32	Lian M, Luo W, Sui Y, Li Z and Hua J: Dietary n-3 PUFA protects mice from con A induced liver injury by modulating regulatory T cells and PPAR-γ expression. PLoS One. 10:e01327412015. View Article : Google Scholar : PubMed/NCBI
33	Liu J, Zhou F, Chen Q, Kang A, Lu M, Liu W, Zang X, Wang G and Zhang J: Chronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3/Nf-κb pathway in 2,4,6-trinitrobenzene sulfonic acid-induced colitis mice. Sci Rep. 5:135582015. View Article : Google Scholar : PubMed/NCBI
34	Lytle C, Tod TJ, Vo KT, Lee JW, Atkinson RD and Straus DS: The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis. 11:231–243. 2005. View Article : Google Scholar : PubMed/NCBI
35	Speca S, Rousseaux C, Dubuquoy C, Rieder F, Vetuschi A, Sferra R, Giusti I, Bertin B, Dubuquoy L, Gaudio E, et al: Novel PPARγ modulator GED-0507-34 levo ameliorates inflammation-driven intestinal fibrosis. Inflamm Bowel Dis. 22:279–292. 2016. View Article : Google Scholar : PubMed/NCBI
36	Kundu P, Ling TW, Korecka A, Li Y, D'Arienzo R, Bunte RM, Berger T, Arulampalam V, Chambon P, Mak TW, et al: Absence of intestinal PPARγ aggravates acute infectious colitis in mice through a lipocalin-2-dependent pathway. PLoS Pathog. 10:e10038872014. View Article : Google Scholar : PubMed/NCBI
37	Hwang D: Fatty acids and immune responses-a new perspective in searching for clues to mechanism. Annu Rev Nutr. 20:431–456. 2000. View Article : Google Scholar : PubMed/NCBI
38	Kim HB, Kumar A, Wang L, Liu GH, Keller SR, Lawrence JC Jr, Finck BN and Harris TE: Lipin 1 represses NFATc4 transcriptional activity in adipocytes to inhibit secretion of inflammatory factors. Mol Cell Biol. 30:3126–3139. 2010. View Article : Google Scholar : PubMed/NCBI
39	Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ and Willett WC: Trans fatty acids and cardiovascular disease. N Engl J Med. 354:1601–1613. 2006. View Article : Google Scholar : PubMed/NCBI
40	Micha R and Mozaffarian D: Trans fatty acids: Effects on cardiometabolic health and implications for policy. Prostaglandins Leukot Essent Fatty Acids. 79:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
41	Ganguly R and Pierce GN: Trans fat involvement in cardiovascular disease. Mol Nutr Food Res. 56:1090–1096. 2012. View Article : Google Scholar : PubMed/NCBI
42	Okada Y, Tsuzuki Y, Ueda T, Hozumi H, Sato S, Hokari R, Kurihara C, Watanabe C, Tomita K, Komoto S, et al: Trans fatty acids in diets act as a precipitating factor for gut inflammation? J Gastroenterol Hepatol. 28(Suppl 4): S29–S32. 2013. View Article : Google Scholar